Prevalence of Osteoporosis in Sickle Cell Disease

Study point of contact

MERLE Blandine
04 72 11 74 80 ext +33
[email protected]
CHAPURLAT Roland, PU, PH
04 72 11 74 82 ext +33
[email protected]

Locations

1 France site

Age

20 to 40 Years

Study type

Observational

Gender

All

Interventions

Other

Compensation

Unknown

About the study

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is
increasing in France, with patients’ life expectancy increasing into developed countries. It
mainly affects populations originating from sub-Saharan Africa. Among the chronic bone
complications associated with sickle cell disease, osteoporosis has previously been
highlighted but remains a poorly known complication in this very particular context. A
dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease
patients living in France may enable better bone management of these patients in the future,
as this problem, specific to their disease, is likely to become more frequent as their life
expectancy increases.

This is a prospective interventional and monocentric study whose objective is to describe the
prevalence of osteoporosis in black patients with sickle cell disease in France

participation requirements

– Black-skinned men and women

– Aged 20 to 40 years old

– Sickle cell patients

– Non-opposition to participate in the study

participation restrictions

– Refusal to participate in the study

– Hemoglobinopathy other than sickle cell disease

– Severe or End Stage Renal Failure

– Long-term corticosteroid therapy (>3 months)

– History of solid cancer or malignant haemopathy

– History of organ transplantation

– Pregnant or breastfeeding woman

– Psychiatric pathology seriously impeding understanding

– Difficulty understanding oral French

Locations

  • Lyon, France, Hôpital Edouard Herriot, 69437 [Recruiting]

More info

View on ClinicalTrials.gov
Site is under construction